News Image

Why the dividend investor may take a look at NASDAQ:GILD.

By Mill Chart

Last update: Apr 17, 2024

Our stock screener has singled out GILEAD SCIENCES INC (NASDAQ:GILD) as a promising choice for dividend investors. NASDAQ:GILD not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Dividend Assessment of NASDAQ:GILD

ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NASDAQ:GILD earns a 7 out of 10:

  • With a Yearly Dividend Yield of 4.49%, GILD is a good candidate for dividend investing.
  • GILD's Dividend Yield is rather good when compared to the industry average which is at 19.20. GILD pays more dividend than 99.15% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.39, GILD pays a better dividend.
  • GILD has been paying a dividend for at least 10 years, so it has a reliable track record.
  • As GILD did not decrease their dividend in the past 5 years, we can say the dividend looks stable.

How We Gauge Health for NASDAQ:GILD

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:GILD has earned a 5 out of 10:

  • The Altman-Z score of GILD (2.58) is better than 73.50% of its industry peers.
  • GILD has a debt to FCF ratio of 3.37. This is a good value and a sign of high solvency as GILD would need 3.37 years to pay back of all of its debts.
  • GILD has a Debt to FCF ratio of 3.37. This is amongst the best in the industry. GILD outperforms 95.38% of its industry peers.

Profitability Analysis for NASDAQ:GILD

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:GILD, the assigned 7 is a significant indicator of profitability:

  • With an excellent Return On Assets value of 9.12%, GILD belongs to the best of the industry, outperforming 97.09% of the companies in the same industry.
  • With an excellent Return On Equity value of 24.81%, GILD belongs to the best of the industry, outperforming 98.12% of the companies in the same industry.
  • The Return On Invested Capital of GILD (12.07%) is better than 97.27% of its industry peers.
  • GILD has a better Profit Margin (20.89%) than 97.61% of its industry peers.
  • Looking at the Operating Margin, with a value of 28.23%, GILD belongs to the top of the industry, outperforming 98.12% of the companies in the same industry.
  • GILD has a Gross Margin of 76.04%. This is amongst the best in the industry. GILD outperforms 85.64% of its industry peers.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Our latest full fundamental report of GILD contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

GILEAD SCIENCES INC

NASDAQ:GILD (4/29/2024, 11:00:09 AM)

66.58

+1.16 (+1.77%)

GILD News

News Image3 hours ago - Zacks Investment ResearchGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

News Imagea day ago - New York TimesU.S. Lags Behind Other Countries in Hepatitis-C Treatment

Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Gilead Sciences (GILD)
News Image3 days ago - InvestorPlace3 Dividend Stocks to Buy at a 52-Week Low in April

Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.

News Image3 days ago - Gilead Sciences, Inc.FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
News Image4 days ago - The Motley FoolGilead Sciences (GILD) Q1 2024 Earnings Call Transcript

GILD earnings call for the period ending March 31, 2024.

News Image4 days ago - InvestorPlaceGILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024

GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image4 days ago - BusinessInsiderGILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...

News Image4 days ago - ChartmillCurious about which S&P500 stocks are showing activity after the closing bell on Thursday?

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.

News Image4 days ago - Investor's Business DailyWill Gilead's Big Veklury Beat Offset A Cancer Drug Miss?

Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.

News Image4 days ago - Gilead Sciences, Inc.Gilead Sciences Announces First Quarter 2024 Financial Results
News Image4 days ago - Market News VideoNoteworthy Thursday Option Activity: NEM, GILD, GOOG
GILD Links
Follow us for more